• Radoslaw Parma, Michael Joner, Francesco Saia, Thomas Cuisset, Victoria Delgado, Josep Rodes-Cabau, Thomas Modine, Eric Van Belle, FovinoLuca NaiLNDepartment of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua Medical School, Padua, Italy., Uri Landes, Hector Alfonso Alvarez-Covarrubias, Mohamed Abdel-Wahab, Jose Luis Zamorano, Matthias Eden, Filippo Cademartiri, Joanna Nawara Skipirzepa, Jana Kurucova, Daniel Greinert, Peter Bramlage, and Giuseppe Tarantini.
• Department of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland.
• Eur. J. Clin. Invest. 2024 Sep 1; 54 (9): e14241e14241.

BackgroundTranscatheter aortic valve implantation (TAVI) is increasingly being used in younger patients and those with lower peri-procedural risk, meaning more patients will live long enough to experience structural valve deterioration (SVD) of the bioprosthesis, indicating repeated TAVI. Experience of repeated TAVI-transcatheter heart valve (THV) implantation into an index THV is limited. This registry aims to assess the peri-procedural and short-term safety, efficacy and durability of repeated TAVI.MethodsThe ReTAVI Prospective observational registry is an investigator-initiated, multicentre, international, prospective registry of patients undergoing repeated TAVI using balloon-expandable SAPIEN prosthesis to evaluate procedural and short-term safety, efficacy and durability as well as anatomical and procedural factors associated with optimal results. The registry will enrol at least 150 patients across 60 high-volume centres. Patients must be ≥18 years old, have had procedural success with their first TAVI, have index THV device failure, intend to undergo repeated TAVI and be considered suitable candidates by their local Heart Team. All patients will undergo a 30-day and 12-month follow-up. The estimated study completion is 2025.ConclusionsThe registry will collect pre-, peri-, postoperative and 12-months data on patients undergoing repeated TAVI procedures with THVs for failure of the index THV and determine VARC-3-defined efficacy and safety at 30 days and functional outcome at 12 months. The registry will expand existing data sets and identify patient characteristics/indicators related to complications and clinical benefits for patients with symptomatic severe calcific degenerative aortic stenosis.© 2024 The Author(s). European Journal of Clinical Investigation published by John Wiley & Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation.

17 keywords...

hide…